(Q37272759)

19 August 2017

1 reference

title

Olanzapine orally disintegrating tablet: a review of efficacy and compliance (English)

1 reference

19 August 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494003&resulttype=core&format=json

14 May 2020

Luis San

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494003&resulttype=core&format=json

14 May 2020

author name string

Marta Casillas

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494003&resulttype=core&format=json

14 May 2020

Antonio Ciudad

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494003&resulttype=core&format=json

14 May 2020

Inmaculada Gilaberte

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494003&resulttype=core&format=json

14 May 2020

publication date

1 January 2008

1 reference

18801113

CNS Neuroscience & Therapeutics

19 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494003&resulttype=core&format=json

14 May 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494003&resulttype=core&format=json

14 May 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494003&resulttype=core&format=json

14 May 2020

page(s)

203-214

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494003&resulttype=core&format=json

Cost of relapse in schizophrenia

14 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2008.00053.X

Mental disorder and criminality: male schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2008.00053.X

Prediction of homelessness within three months of discharge among inpatients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2008.00053.X

Determinants of medication compliance in schizophrenia: empirical and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2008.00053.X

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2008.00053.X

Rating of medication influences (ROMI) scale in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2008.00053.X

Optimizing adherence to pharmaceutical care plans

21 January 2018

1 reference

12 December 2020

Patient compliance with drug therapy in schizophrenia. Economic and clinical issues

1 reference

12 December 2020

Olanzapine: an updated review of its use in the management of schizophrenia

1 reference

12 December 2020

Longitudinal study of brain morphology in first episode schizophrenia

1 reference

12 December 2020

Compliance with antipsychotic treatment.

1 reference

12 December 2020

Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis.

1 reference

12 December 2020

Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications

1 reference

12 December 2020

Dissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophrenia

1 reference

12 December 2020

Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia

1 reference

12 December 2020

Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia

1 reference

12 December 2020

Increased suicide attempt rate among patients interrupting use of atypical antipsychotics

1 reference

12 December 2020

Factors influencing compliance in schizophrenia patients

1 reference

12 December 2020

Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia

1 reference

12 December 2020

Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services

1 reference

12 December 2020

Orally disintegrating olanzapine: a possible alternative to injection of antipsychotic drugs

1 reference

12 December 2020

New antipsychotics, compliance, quality of life, and subjective tolerability--are patients better off?

1 reference

12 December 2020

Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets

1 reference

12 December 2020

Olanzapine: a review of its use in the management of bipolar I disorder

1 reference

12 December 2020

Adolescent weight loss during treatment with olanzapine

1 reference

12 December 2020

Intramuscular olanzapine: a review of its use in the management of acute agitation

1 reference

12 December 2020

Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses

1 reference

12 December 2020

Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis

1 reference

12 December 2020

Adherence to Medication

1 reference

12 December 2020

Orally disintegrating antipsychotics may promote compliance and adherence in patients with schizophrenia

1 reference

12 December 2020

Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers

1 reference

12 December 2020

Impact of orally disintegrating olanzapine on use of intramuscular antipsychotics, seclusion, and restraint in an acute inpatient psychiatric setting

1 reference

12 December 2020

Long-term treatment with atypical antipsychotics and risk of weight gain

1 reference

12 December 2020

Relapse prevention and recovery in the treatment of schizophrenia

1 reference

12 December 2020

A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia.

1 reference

12 December 2020

Orally disintegrating olanzapine for the treatment of a manic patient with esophageal stricture plus chronic pharyngitis

1 reference

12 December 2020

Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients.

1 reference

12 December 2020

[Compliance in psychiatry: results of a survey of depressed patients using orally disintegrating tablet]

1 reference

12 December 2020

Olanzapine orally-disintegrating tablet in severe psychotic agitation: a naturalistic study.

1 reference

12 December 2020

Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability

1 reference

12 December 2020

Sublingual use of olanzapine in combination with alprazolam to treat agitation in a terminally ill patient receiving parenteral nutrition.

1 reference

12 December 2020

Association of acute symptoms and compliance attitude in noncompliant patients with schizophrenia

1 reference

12 December 2020

Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets

1 reference

12 December 2020

Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial

1 reference

12 December 2020

Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients

1 reference

12 December 2020

Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients

1 reference

12 December 2020

Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study

1 reference

12 December 2020

Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates

1 reference

12 December 2020

Serotonin contracts the isolated rat pylorus via a 5-HT2-like receptor

1 reference

12 December 2020

Compliance with treatment regimens in chronic asymptomatic diseases

1 reference

12 December 2020

Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients

1 reference

12 December 2020

Drug-delivery products and the Zydis fast-dissolving dosage form

1 reference

12 December 2020

10.1111/J.1755-5949.2008.00053.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494003&resulttype=core&format=json

release_pmyanpqs3be4ve76npokm7jq5m

14 May 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pmyanpqs3be4ve76npokm7jq5m

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494003&resulttype=core&format=json

14 May 2020

18801113

1 reference